Selenium may protect from high risk-bladder cancer
Mutations in the nuclear intermediate filament lamin A/C (LMNA) gene are associated with Emery-Dreifuss muscular dystrophy, but cause the disease by unknown mechanisms. Méjat et al. show that one mechanism involves the disruption of neuromuscular junctions. The study will appear online on Monday, January 5, 2009 and in the January 12, 2009 print issue of
Full Post: How loss or mutation of LMNA gene causes Emery-Dreifuss muscular dystrophy
A study published in the December issue of Cancer Prevention Research, a journal of the American Association for Cancer Research, suggests that selenium, a trace mineral found in grains, nuts and meats, may aid in the prevention of high-risk bladder cancer.
Researchers from Dartmouth Medical School compared selenium levels in 767 individuals newly diagnosed with bladder cancer to the levels of 1,108 individuals from the general population. Findings showed an inverse association between selenium and bladder cancer among women, some smokers and those with p53 positive bladder cancer.
In the entire study population, there was no inverse association between selenium and bladder cancer, but women (34 percent), moderate smokers (39 percent) and those with p53 positive cancer (43 percent) had significant reductions in bladder cancer with higher rates of selenium.
“There are different pathways by which bladder cancer evolves and it is thought that one of the major pathways involves alterations in the p53 gene,” said corresponding author Margaret Karagas, Ph.D., professor of community and family medicine of the Norris Cotton Cancer Center at Dartmouth. “Bladder cancers stemming from these alternations are associated with more advanced disease.”
While other studies have shown a similar association between selenium and bladder cancer among women, this study is one of the first to show an association between selenium and p53 positive bladder cancer.
“Ultimately, if it is true that selenium can prevent a certain subset of individuals, like women, from developing bladder cancer, or prevent certain types of tumors, such as those evolving through the p53 pathway, from developing, it gives us clues about how the tumors could be prevented in the future and potentially lead to chemopreventive efforts,” Karagas said.
Karagas hopes to replicate these findings on a larger scale in order to examine the connection between selenium and bladder cancer in women and those with p53 tumors, as well as with patient prognosis.
The Great American Smokeout is this Thursday, and the American Urological Association (AUA) gives smokers another good reason to quit: Smoking causes bladder cancer. Only about 33 percent of people know that smoking is a leading risk factor for the disease, according to a new study published in The Journal of Urology, the official journal
Full Post: Smoking causes bladder cancer
In perhaps the largest cancer chemoprevention trial ever conducted, researchers have found that supplementation with vitamin E or selenium, alone or in combination, was not associated with a lower risk of prostate cancer or other cancers. This study, along with another cancer prevention study, will be published in the January 7 issue of JAMA, the
Full Post: Neither vitamin E nor selenium reduce risk of prostate cancer
Canadian researchers are trying to answer why some smokers develop lung cancer while others remain disease free, despite similar lifestyle changes. Results were presented at the American Association for Cancer Research’s Seventh Annual International Conference on Frontiers in Cancer Prevention Research. According to the Centers for Disease Control and Prevention, more people die from lung
Full Post: Why only some former smokers develop lung cancer
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. The findings, presented today
Full Post: Early-stage breast cancer patients with HER2 positive tumors at increased risk of recurrence
Women who have a strong family history of breast cancer are over four times more likely to develop the disease than the general population, according to research published in the British Journal of Cancer. This is the first time the risk for women who do not have a faulty BRCA gene but have one first-degree
Full Post: Breast cancer four times more likely in women with strong family history